e-SPACE Cardio-Renal-Metabolic 2023
Published: 25 March 2023
Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance)Up Next
56m 38sPart 1 | Session 3 Plenary session 2 – SGLT2 updates
58m 54sPart 1 | Session 5 Plenary session 3 – Weight management in CRM disease
1h 6m 3sPart 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients
58m 41sPart 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease
59m 5sPart 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches
59m 17sPart 2 | Session 5 Plenary session 9 – Managing “metals”
1h 2m 16sPart 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
1h 3m 10sPart 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
1h 1m 47sPart 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
58m 8sPart 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Professor of Cardiology
Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.
Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.
Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and…
Professor of Medicine
Prof Paola Fioretto is a Professor of Medicine at University of Padova, Padua, IT.
Her research interest includes the effects of glucose lowering therapies on the development and progression of diabetic kidney disease.
Prof Fioretto started her research on renal physiology in diabetes and during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes.
Prof Michel Jadoul is a Clinical Professor at Université catholique de Louvain, Ottignies-Louvain-la-Neuve, BE.
Prof Jadoul's clinical activities include the follow-up of hemodialysis and CKD patients. His main research interests include hepatitis C, beta2m amyloidosis and other complications in hemodialysis patients, as well as CV complications after kidney TP and various causes of kidney disease (especially drugs).
He has (co)-authored over 330 scientific papers, most of them published in major nephrology journals.